Loading clinical trials...
Loading clinical trials...
The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.
This study will be achieved by studying the acute effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis and a cannabinoid-1 receptor (CB1R) agonist, on a wide range of memory tasks in healthy human subjects.
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
Yes
VA Connecticut Healthcare System
West Haven, Connecticut, United States
Start Date
February 1, 2015
Primary Completion Date
August 10, 2018
Completion Date
December 1, 2025
Last Updated
June 10, 2025
80
ESTIMATED participants
THC
DRUG
Placebo
DRUG
Lead Sponsor
Yale University
NCT05855668
NCT07455929
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions